Business
Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal
ORION CORPORATION PRESS RELEASE 30 SEPTEMBER 2025 at 13.00 EEST Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal Orion to discontinue development of ODM-105 for insomnia.ODM-105 (tasipimidine) was well tolerated. Detailed results, including safety data, and their assessment are to be finalized. Orion Corporation today announced that its candidate ODM-105 (tasipimidine) did not meet the primary goal in the clinical Phase 2 UNITAS study for the treatment of patients with inso
About this update from Orion Corp.
[{"type":"image","alt":"Orion Oyj","displaySize":"","headline":null,"caption":"Orion Oyj","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":118,"url":"https://media.zenfs.com/en/globenewswire.com/81ce103a881cae9326d4e01207e6d4b0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PqzIu4PIU0vnnZUA5EUYng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/81ce103a881cae9326d4e01207e6d4b0","width":300,"height":118}},"lazy":false},{"type":"text","content":"ORION CORPORATION PRESS RELEASE 30 SEPTEMBER 2025 at 13.00 EEST","length":71,"tagName":"p"},{"type":"text","content":"Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal ","length":70,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Orion to discontinue development of ODM-105 for insomnia.","length":57,"tagName":"p"}]},{"val":[{"type":"text","content":"ODM-105 (tasipimidine) was well tolerated. Detailed results, including safety data, and their assessment are to be finalized.","length":125,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":182,"olType":false},{"type":"text","content":"Orion Corporation today announced that its candidate ODM-105 (tasipimidine) did not meet the primary goal in the clinical Phase 2 UNITAS study for the treatment of patients with insomnia. According to the study results, ODM-105 did not significantly improve insomnia-related symptoms such as time to fall asleep or sleep duration compared with placebo. ODM-105 was generally safe and well tolerated. Detailed results, including safety data, and their assesment are not yet finalized.","length":483,"tagName":"p"},{"type":"text","content":"“We are disappointed that our study did not meet its primary goal. Our biggest regret is that we’re not able to provide a new and more efficient treatment option for people suffering from insomnia”, said Professor Outi Vaarala, Executive Vice President, Innovative Medicines and Research & Development at Orion. “Recruitment for the UNITAS study was faster than expected, which enabled an earlier read-out of efficacy signals. On the other hand, it also reflects the huge unmet need for new insomnia treatments that still remains. We will focus our efforts and resources on advancing our other assets both in research and clinical phases.”","length":643,"tagNam...